justiceforb_85 Posted - 10/24/24

$NBTX anticipate a bright future for this one. But long period of time until next data read-out.

biotechbull2020 Posted - 1 month ago

$NBTX this is gonna go hard today!

Stock_Titan Posted - 2 months ago

$NBTX NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results https://www.stocktitan.net/news/NBTX/nanobiotix-provides-business-update-and-reports-half-year-2024-hfyshlwokd41.html

Stock_Titan Posted - 2 months ago

$NBTX NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth https://www.stocktitan.net/news/NBTX/nanobiotix-announces-two-key-supervisory-board-additions-intended-to-5n5oglykef17.html

Manipulation13F Posted - 2 months ago

$NBTX watching 👀

erevnon Posted - 08/28/24

Guggenheim initiates coverage on Nanobiotix $NBTX at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

Thestocktraderhubzee Posted - 08/28/24

$NBTX Guggenheim Initiates Coverage On Nanobiotix with Buy Rating, Announces Price Target of $12

topstockalerts Posted - 08/28/24

$NBTX waking up

AZOZ Posted - 08/28/24

Good morning followers 💵 Small cap premarket movers $SVRE $JBDI $AIXI $NBTX $BNZI

justiceforb_85 Posted - 08/27/24

$NBTX when do we anticipate release of results from phase III head/neck cancer trial?

Stock_Titan Posted - 3 months ago

$NBTX Voting Rights and Shares Capital of the Company https://www.stocktitan.net/news/NBTX/voting-rights-and-shares-capital-of-the-lvwohllr0fd2.html

fda_tracker Posted - 4 months ago

$NBTX Phase 3 trial w/est Jul completion date NCT04892173: https://www.clinicaltrials.gov/study/NCT04892173 Trial Tracker: https://www.fdatracker.com/trial-tracker/

Stock_Titan Posted - 4 months ago

$NBTX Voting Rights and Shares Capital of the Company https://www.stocktitan.net/news/NBTX/voting-rights-and-shares-capital-of-the-t2wjrdd3ci6v.html

Laurapicksright Posted - 06/26/24

$SIRI Whens the merger 😍😍😍 Watching $VLCN $CHNR $AUST $NBTX

DonCorleone77 Posted - 06/25/24

$NBTX Nanobiotix initiated with a Buy at Stifel Stifel analyst Clemence Thiers initiated coverage of Nanobiotix with a Buy rating and EUR 16 price target, implying 304% potential upside to the current share price. NBTXR3, Nanobiotix's lead asset, is an innovative radioenhancer designed to improve the effectiveness of radiotherapy by amplifying the radiation dose intratumorally, triggering both local and systemic responses, the analyst tells investors in a research note. The firm says the company has an innovative physical-based approach to cancer treatment, which is supported by collaborations with prestigious partners.

Stock_Titan Posted - 5 months ago

$NBTX Voting Rights and Shares Capital of the Company https://www.stocktitan.net/news/NBTX/voting-rights-and-shares-capital-of-the-1mfd9hbc7lcw.html

DonCorleone77 Posted - 5 months ago

$NBTX Nanobiotix announces new data from Study 1100 Nanobiotix announced new data from Study 1100, a U.S. Phase 1 dose escalation and dose expansion study evaluating radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors as a second-or-later line therapy for patients with advanced solid and metastatic tumors. These data were presented at the 2024 Annual Meeting of the American Society for Clinical Oncology. At the data cutoff, NBTXR3 injection followed by standard RT and anti-PD-1 therapy was feasible and well tolerated in 68 heavily pretreated patients with 2L+ R/M-HNSCC. Serious Grade 3+ adverse events related to the combined therapeutic regimen occurred in 8.8% of patients. Investigators concluded that promising early signals of efficacy were observed in Study 1100 patients with naive or resistant 2L+ R/M-HNSCC who received RT-activated NBTXR3 followed by anti-PD-1. Disease control was observed in both naive and resistant R/M-HNSCC patients, highlighting the potential for NBTXR3 in this population. Overall, these results warrant further exploration in randomized trials for both naive and resistant R/M-HNSCC patients. Nanobiotix expects to provide first data from cohort 3 of the Study 1100 dose expansion part in 2025.

Stock_Titan Posted - 5 months ago

$NBTX Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy https://www.stocktitan.net/news/NBTX/nanobiotix-announces-new-data-showing-disease-control-and-tumor-15s4icvyluwn.html

Stock_Titan Posted - 05/28/24

$NBTX NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call https://www.stocktitan.net/news/NBTX/nanobiotix-announces-presentation-of-new-data-from-phase-1-g0ys5d661znw.html

Stock_Titan Posted - 05/22/24

$NBTX NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update https://www.stocktitan.net/news/NBTX/nanobiotix-provides-first-quarter-2024-operational-and-financial-9pzt1ev5e1hu.html

Stock_Titan Posted - 6 months ago

$NBTX Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth https://www.stocktitan.net/news/NBTX/nanobiotix-announces-progress-in-global-nbtxr3-development-t3jzjczw15yx.html

Stock_Titan Posted - 6 months ago

$NBTX Voting Rights and Shares Capital of the Company https://www.stocktitan.net/news/NBTX/voting-rights-and-shares-capital-of-the-upzyahc2amnv.html

Stock_Titan Posted - 6 months ago

$NBTX NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 https://www.stocktitan.net/news/NBTX/nanobiotix-to-announce-first-quarter-operational-and-financial-48rjw3mdoa85.html

DonCorleone77 Posted - 6 months ago

$NBTX $JNJ Nanobiotix announces FDA issuance of Study May Proceed Letter for NBTXR3 study Nanobiotix (NBTX) announced that the FDA issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for the treatment of patients with stage 3, unresectable non-small cell lung cancer. An IND to support this trial was submitted by the global trial sponsor, Johnson & Johnson Enterprise Innovation Inc., a Johnson & Johnson (JNJ) company.

Stock_Titan Posted - 6 months ago

$NBTX NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer https://www.stocktitan.net/news/NBTX/nanobiotix-announces-us-fda-protocol-acceptance-for-new-randomized-crq7rw46sz85.html

Stock_Titan Posted - 04/24/24

$NBTX NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results https://www.stocktitan.net/news/NBTX/nanobiotix-provides-business-update-and-reports-full-year-2023-q21g25mbr5yj.html

Stock_Titan Posted - 7 months ago

$NBTX NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 https://www.stocktitan.net/news/NBTX/nanobiotix-to-announce-fourth-quarter-and-full-year-2023-operational-98qob21jbfaa.html

Stock_Titan Posted - 7 months ago

$NBTX Voting Rights and Shares Capital of the Company https://www.stocktitan.net/news/NBTX/voting-rights-and-shares-capital-of-the-s8mf0fkt0sl9.html

AlertsAndNews Posted - 7 months ago

Updated Gappers in after hours trading $MRIN $INAB $JAGX $JZXN $NBTX Enjoy your evening, see you in the AM for CPI!

Monster_Mover_Stocks Posted - 7 months ago

$NBTX End of after-hours low float sub $10 volume buzz leader occurring late in the day with several daily chart indicator highs. Ending after-hours price is $6.38. Watchlist worthy.